PT3766884T - Forma cristalina e tipo de sal de composto de triazolopirimidina e método de preparação associado - Google Patents
Forma cristalina e tipo de sal de composto de triazolopirimidina e método de preparação associadoInfo
- Publication number
- PT3766884T PT3766884T PT197936222T PT19793622T PT3766884T PT 3766884 T PT3766884 T PT 3766884T PT 197936222 T PT197936222 T PT 197936222T PT 19793622 T PT19793622 T PT 19793622T PT 3766884 T PT3766884 T PT 3766884T
- Authority
- PT
- Portugal
- Prior art keywords
- preparation
- crystal form
- method therefor
- salt type
- triazolopyrimidine compound
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- -1 triazolopyrimidine compound Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810399876 | 2018-04-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3766884T true PT3766884T (pt) | 2022-03-31 |
Family
ID=68294924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT197936222T PT3766884T (pt) | 2018-04-28 | 2019-04-28 | Forma cristalina e tipo de sal de composto de triazolopirimidina e método de preparação associado |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11649239B2 (enExample) |
| EP (1) | EP3766884B1 (enExample) |
| JP (1) | JP7406691B2 (enExample) |
| CN (1) | CN112105617B (enExample) |
| DK (1) | DK3766884T3 (enExample) |
| ES (1) | ES2908424T3 (enExample) |
| PL (1) | PL3766884T3 (enExample) |
| PT (1) | PT3766884T (enExample) |
| WO (1) | WO2019206336A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11649239B2 (en) * | 2018-04-28 | 2023-05-16 | Medshine Discovery Inc. | Crystal form a of (5-amino-8-(2-methyl-6-(trifluoromethyl)pyridin-4-yl)-7-phenyl-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)methanol (compound 1) |
| TWI820209B (zh) * | 2018-09-12 | 2023-11-01 | 大陸商迪哲（江蘇）醫藥股份有限公司 | 三唑并－嘧啶化合物及其用途 |
| WO2020106560A1 (en) | 2018-11-20 | 2020-05-28 | Merck Sharp & Dohme Corp. | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use |
| MX2022002219A (es) * | 2019-08-26 | 2022-06-14 | Incyte Corp | Triazolopirimidinas como inhibidores de a2a/a2b. |
| CN120022278A (zh) * | 2023-11-22 | 2025-05-23 | 英诺湖医药(杭州)有限公司 | 用于治疗癌症的化合物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2284737C (en) | 1997-03-24 | 2007-03-13 | Kyowa Hakko Kogyo Co., Ltd. | [1,2,4]triazolo[1,5-c]pyrimidine derivatives |
| TW200300686A (en) | 2001-11-30 | 2003-06-16 | Schering Corp | Adenosine A2a receptor antagonists |
| AU2003272886A1 (en) | 2002-09-24 | 2004-04-19 | Kyowa Hakko Kogyo Co., Ltd. | (1,2,4)-TRIAZOLO(1,5-c)PYRIMIDINE DERIVATIVE |
| JP7065113B2 (ja) | 2017-04-07 | 2022-05-11 | 南京明徳新薬研発有限公司 | Ａ２Ａ受容体阻害剤としての［１，２，４］トリアゾロ［１，５－ｃ］ピリミジン誘導体 |
| US11649239B2 (en) * | 2018-04-28 | 2023-05-16 | Medshine Discovery Inc. | Crystal form a of (5-amino-8-(2-methyl-6-(trifluoromethyl)pyridin-4-yl)-7-phenyl-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)methanol (compound 1) |
-
2019
- 2019-04-28 US US17/044,127 patent/US11649239B2/en active Active
- 2019-04-28 ES ES19793622T patent/ES2908424T3/es active Active
- 2019-04-28 PT PT197936222T patent/PT3766884T/pt unknown
- 2019-04-28 JP JP2021508055A patent/JP7406691B2/ja active Active
- 2019-04-28 CN CN201980023228.3A patent/CN112105617B/zh active Active
- 2019-04-28 WO PCT/CN2019/084822 patent/WO2019206336A1/zh not_active Ceased
- 2019-04-28 PL PL19793622.2T patent/PL3766884T3/pl unknown
- 2019-04-28 EP EP19793622.2A patent/EP3766884B1/en active Active
- 2019-04-28 DK DK19793622.2T patent/DK3766884T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3766884A1 (en) | 2021-01-20 |
| PL3766884T3 (pl) | 2022-07-18 |
| CN112105617A (zh) | 2020-12-18 |
| US20210094957A1 (en) | 2021-04-01 |
| WO2019206336A1 (zh) | 2019-10-31 |
| JP2021522335A (ja) | 2021-08-30 |
| EP3766884A4 (en) | 2021-03-31 |
| EP3766884B1 (en) | 2022-02-09 |
| ES2908424T3 (es) | 2022-04-29 |
| JP7406691B2 (ja) | 2023-12-28 |
| DK3766884T3 (da) | 2022-03-28 |
| CN112105617B (zh) | 2022-04-05 |
| US11649239B2 (en) | 2023-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202007037B (en) | Crystal form of c-met inhibitor and salt form thereof and preparation method therefor | |
| PL3766884T3 (pl) | Postać krystaliczna i rodzaj soli związku triazolopirymidynowego oraz sposób jej wytwarzania | |
| EP3287444A4 (en) | New crystal form of lenvatinib methanesulfonate salt and preparation method thereof | |
| EP3763713A4 (en) | CRYSTAL FORM AND SALT FORM OF A PYRIDOIMIDAZOLE COMPOUND AND THE METHOD FOR MANUFACTURING IT | |
| ZA202103712B (en) | D-psicose crystal and preparation method therefor | |
| IL283288B (en) | A method for the production of a new nitrogen-containing compound or a salt thereof and the production of an intermediate of a new nitrogen-containing compound or a salt thereof | |
| EP3383844B8 (en) | Process for the preparation of carboprost and its tromethamine salt | |
| HUE062473T2 (hu) | Updacitinib só vegyület és eljárás elõállítására | |
| IL319797B1 (en) | Method for synthesizing a furoimidazopyridine compound, a crystalline form of a furoimidazopyridine compound, and a crystalline form of a salt thereof | |
| EP3805229A4 (en) | SALT OF A CONDENSED RING PYRIMIDINE COMPOUND, ITS CRYSTAL FORM AND PROCESS FOR ITS PREPARATION AND ITS USE | |
| ZA202004055B (en) | Salt of phenylpropionamide derivative and preparation method therefor | |
| PL4061772T3 (pl) | Sposób wytwarzania argyrodytu litowego | |
| EP3677575A4 (en) | CRYSTALLINE FORM OF OZANIMODHYDROCHLORIDE AND PRODUCTION METHOD THEREFOR | |
| EP3489250A4 (en) | CRYSTALLINE FORM OF A DAPAGLIFLOZIN INTERMEDIATE AND PRODUCTION METHOD THEREFOR | |
| EP3842426A4 (en) | PREPARATION PROCESS OF PYRROLO-AMINO-PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | |
| PT3511333T (pt) | Forma cristalina e forma de sal do composto 7hpirrolo[ 2,3-d]pirimidina e método de preparação para o mesmo | |
| EP3272751A4 (en) | Crystal form of ipi-145 and preparation method thereof | |
| PT3725786T (pt) | Forma cristalina e forma salina de inibidor de tgf-bri e método de preparação das mesmas | |
| EP3369733A4 (en) | Crystal form of 4h-pyrazolo[1,5- ]benzoimidazole compound, preparation method therefor and intermediate thereof | |
| IL274274A (en) | Salt form and crystal form of compound as FGFR4 inhibitor and method of their preparation | |
| EP3269710A4 (en) | Nintedanib diethanesulfonate salt crystal and preparation method and use thereof | |
| IL263868A (en) | Crystal structures of aminomethyl-converted tetracyclines and processes for their preparation | |
| EP3741746A4 (en) | CRYSTAL FORM OF OXOPICOLINAMIDE DERIVATIVE AND MANUFACTURING PROCESS FOR IT | |
| EP3444248A4 (en) | CRYSTALLINE SHAPE OF BREXPIPRAZOLE AND PREPARATION METHOD THEREOF | |
| EP3257851A4 (en) | Salt form and crystal form of 1,2,5 thiadiazolidin-1,1-dioxide, preparation method thereof and intermediate |